Inhibition of PRC2 activity by a gain-of-function H3 mutation found in pediatric glioblastoma.
about
Endogenous mammalian histone H3.3 exhibits chromatin-related functions during developmentZMYND11 links histone H3.3K36me3 to transcription elongation and tumour suppressionDistinct H3F3A and H3F3B driver mutations define chondroblastoma and giant cell tumor of boneEpigenetic modulators, modifiers and mediators in cancer aetiology and progressionTargeting EZH2 in cancerProgress in epigenetic histone modification analysis by mass spectrometry for clinical investigationsThe complexity of epigenetic diseasesChromatin Dynamics in Vivo: A Game of Musical ChairsPre-Clinical Models of Diffuse Intrinsic Pontine GliomaPolycomb Group (PcG) Proteins and Human Cancers: Multifaceted Functions and Therapeutic ImplicationsPathology, Molecular Genetics, and Epigenetics of Diffuse Intrinsic Pontine GliomaFuture Clinical Trials in DIPG: Bringing Epigenetics to the ClinicHistone modifications and a choice of variant: a language that helps the genome express itselfMolecular characteristics of pediatric high-grade gliomasEpigenetic dysregulation: a novel pathway of oncogenesis in pediatric brain tumorsHistone H3 mutations--a special role for H3.3 in tumorigenesis?Chromatin targeting drugs in cancer and immunityEvery amino acid matters: essential contributions of histone variants to mammalian development and diseaseNew insights and challenges in mismatch repair: getting over the chromatin hurdleHistone variants: the tricksters of the chromatin worldChromatin signatures of cancerGain-of-function mutation of chromatin regulators as a tumorigenic mechanism and an opportunity for therapeutic interventionRNase P protein subunit Rpp29 represses histone H3.3 nucleosome depositionStructural basis of histone H3K27 trimethylation by an active polycomb repressive complex 2Diverse involvement of EZH2 in cancer epigeneticsRecurrent activating ACVR1 mutations in diffuse intrinsic pontine gliomaCauses of genome instability: the effect of low dose chemical exposures in modern societyPre-Clinical Study of Panobinostat in Xenograft and Genetically Engineered Murine Diffuse Intrinsic Pontine Glioma ModelsPD-0332991, a CDK4/6 inhibitor, significantly prolongs survival in a genetically engineered mouse model of brainstem gliomaA high-throughput in vitro drug screen in a genetically engineered mouse model of diffuse intrinsic pontine glioma identifies BMS-754807 as a promising therapeutic agentZFHX4 interacts with the NuRD core member CHD4 and regulates the glioblastoma tumor-initiating cell stateA histone H3K9M mutation traps histone methyltransferase Clr4 to prevent heterochromatin spreadingFunctionally defined therapeutic targets in diffuse intrinsic pontine gliomaWeaver Syndrome-Associated EZH2 Protein Variants Show Impaired Histone Methyltransferase Function In VitroDiffuse Intrinsic Pontine Glioma: New Pathophysiological Insights and Emerging Therapeutic TargetsHistone variants and epigenetics."Modifying" My Career toward Chromatin Biology.Single cell analysis of RNA-mediated histone H3.3 recruitment to a cytomegalovirus promoter-regulated transcription site.Homozygosity mapping and sequencing identify two genes that might contribute to pointing behavior in hunting dogs.Molecular basis for oncohistone H3 recognition by SETD2 methyltransferase
P2860
Q21198852-C3896263-382C-4A24-8337-CC904E4C79B0Q24338606-DB494BFE-FD1A-4F1B-8F19-73C9FD38E560Q24595521-C5074594-2F01-472D-AEDF-358DB303CF8FQ26766149-A861D070-33E5-4D18-A65B-138B64748A1FQ26769027-BCC60B44-E829-4216-8535-D12643F8BE3DQ26781745-4CCC6467-B53F-4B8F-9FAA-83D8BD9FE28FQ26784416-115F5400-2C2A-4457-8DD0-3E943F781CA8Q26799305-E11136A4-1403-4E6A-9803-118084142AE7Q26799976-F8A402FF-C0D9-440C-BF21-89F209D295A2Q26801380-0A0AF6B1-E249-4A96-B5B1-164E06DB4988Q26801528-3FD14D2B-28AE-49E6-9EF1-AE5DF42F17BAQ26801858-FD8CF134-5ADE-41E1-A9F6-A4C7D2DEED0FQ26823316-F5DD5FDB-DFF9-4495-8EA0-AB5AD637B292Q26860786-57705C50-0773-441A-B7F7-BA07ABD89F6AQ26864920-3674BE00-A2D5-405E-AB2B-59B553E6D713Q26865965-C7934A1F-9C2D-4120-9D6B-B2A67D6E1ECFQ26999888-D6D121B9-2EAF-40AD-A1CD-259E4F0649D2Q27008522-01D56073-BE0F-412D-8C4D-DFA2E428EDBAQ27011117-31B2205C-A187-4F01-BEAE-1812981B79CCQ27021264-E1EF3E85-89B6-4A3E-9359-F186302FCA12Q27024162-5DEE17FC-2E4C-4A74-94E4-D35F9AD8B67BQ27024233-07DC5428-8417-449C-B989-65868B82C16CQ27306288-9AAE93AB-3F79-4141-9D80-CA19DF801D8EQ27702306-3CE759BC-3B7B-4D2C-AD24-C93977E3CD32Q28084911-A4FEAFCB-75D8-453E-80A2-A17CB1C32D94Q28237518-C991D2A3-17EB-47B6-9138-8C3FCBF47232Q28388277-896A330C-9363-46DB-8DD6-0C064586DA24Q28468398-4A23A63B-ED85-42C4-AC15-79D1E895F639Q28533981-9718E617-61E9-46CB-9ED7-CC2873E216AFQ28543923-5DE19081-1166-4293-9A7B-13A0D0DE5F32Q28594320-A7111FF2-ADA3-4DFB-A6B5-E82911738993Q28829593-9E858480-717F-4D06-994E-B7190EB49063Q28833173-31FFEB9D-5CB5-47E6-A3FF-2462C3AEE8E7Q29147503-644A06A5-5678-4EA9-90E3-3114EE3A3367Q30251385-276487CD-B825-4D3F-B923-33B23DE33B66Q30301007-81F0B335-0B77-4CD0-A711-CB1002040DF3Q30358103-BF98D5DD-9040-435C-9EC8-E275E819241EQ30541321-9358947C-1F1D-45A0-8D1F-68A543C852A2Q30665213-7F1A1572-39DF-4FED-8E6F-68B1C943CF63Q30794597-A0F5BF69-3D58-4C20-855A-15823F8089A0
P2860
Inhibition of PRC2 activity by a gain-of-function H3 mutation found in pediatric glioblastoma.
description
2013 nî lūn-bûn
@nan
2013年の論文
@ja
2013年学术文章
@wuu
2013年学术文章
@zh-cn
2013年学术文章
@zh-hans
2013年学术文章
@zh-my
2013年学术文章
@zh-sg
2013年學術文章
@yue
2013年學術文章
@zh
2013年學術文章
@zh-hant
name
Inhibition of PRC2 activity by ...... und in pediatric glioblastoma.
@en
type
label
Inhibition of PRC2 activity by ...... und in pediatric glioblastoma.
@en
prefLabel
Inhibition of PRC2 activity by ...... und in pediatric glioblastoma.
@en
P2093
P2860
P356
P1433
P1476
Inhibition of PRC2 activity by ...... und in pediatric glioblastoma.
@en
P2093
Benjamin A Garcia
C David Allis
Francisco Cordero
Laura A Banaszynski
Manuel M Müller
Matthew S Koletsky
Oren J Becher
Tom W Muir
P2860
P304
P356
10.1126/SCIENCE.1232245
P407
P577
2013-03-28T00:00:00Z